Sarepta Therapeutics (NASDAQ:SRPT) Earns “Underperform” Rating from Needham & Company LLC

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “underperform” rating reaffirmed by analysts at Needham & Company LLC in a research report issued on Thursday,Benzinga reports.

A number of other brokerages also recently weighed in on SRPT. Wedbush cut their price target on shares of Sarepta Therapeutics from $34.00 to $29.00 and set an “outperform” rating for the company in a report on Monday, March 2nd. Wells Fargo & Company decreased their price objective on shares of Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. Mizuho boosted their price objective on shares of Sarepta Therapeutics from $26.00 to $31.00 and gave the company an “outperform” rating in a research report on Thursday, March 12th. Oppenheimer restated an “outperform” rating and set a $37.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, March 19th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $30.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, March 3rd. Nine investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $32.30.

Sarepta Therapeutics Stock Down 7.9%

Shares of NASDAQ SRPT opened at $19.97 on Thursday. The stock has a market capitalization of $2.10 billion, a P/E ratio of -2.37, a PEG ratio of 0.34 and a beta of 0.42. The stock’s fifty day moving average is $18.69 and its 200 day moving average is $19.99. Sarepta Therapeutics has a 52 week low of $10.41 and a 52 week high of $72.05. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.48 and a current ratio of 2.32.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($2.71). The firm had revenue of $442.93 million for the quarter, compared to the consensus estimate of $390.95 million. Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The company’s revenue for the quarter was down 32.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.90 EPS. Sell-side analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the company’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $17.02, for a total value of $123,207.78. Following the completion of the transaction, the director owned 1,765 shares of the company’s stock, valued at $30,040.30. This represents a 80.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Kestra Advisory Services LLC bought a new stake in Sarepta Therapeutics in the fourth quarter worth approximately $25,000. iSAM Funds UK Ltd bought a new position in shares of Sarepta Therapeutics during the 3rd quarter worth approximately $25,000. Ancora Advisors LLC grew its position in shares of Sarepta Therapeutics by 200.0% during the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after buying an additional 1,000 shares during the period. Byrne Asset Management LLC acquired a new stake in shares of Sarepta Therapeutics during the 3rd quarter worth approximately $33,000. Finally, Allworth Financial LP increased its stake in shares of Sarepta Therapeutics by 2,098.8% in the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 1,721 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Key Stories Impacting Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Early siRNA Phase 1/2 data (SRP‑1001, SRP‑1003) impressed investors — strong target knockdown, safety and muscle delivery signals sparked the share rally and lifted sentiment on Sarepta. SRPT Stock Surges on Promising Early Results From siRNA Programs
• Positive Sentiment: Options flow has been very bullish — large volume of call purchases suggests traders are positioning for further upside or continued momentum. Investors Buy Large Volume of Call Options on Sarepta Therapeutics (NASDAQ:SRPT)
• Positive Sentiment: At least one major shop (reported coverage) raised its price target after the data, which helped validate the clinical news and contributed to the rally. Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results
• Neutral Sentiment: Analyst consensus remains cautious/neutral overall — the stock’s average rating is a “Hold,” reflecting mixed views despite the clinical upside. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Rating of “Hold” from Brokerages
• Neutral Sentiment: Valuation and longer‑term upside are being reassessed: several writeups model potential upside but note the one‑day rebound and remaining execution risks. Assessing Sarepta Therapeutics (SRPT) Valuation After Early siRNA Trial Results
• Negative Sentiment: Some sell/underperform stances persist — Citigroup raised its PT but kept a sell rating, and Needham reaffirmed underperform, highlighting continued skepticism among parts of the sell‑side. These views can cap rallies if the broader data set or guidance don’t follow through. Brokerage Notes (Citigroup/Needham)
• Negative Sentiment: Cautious takeaways from analysts/commentators emphasize the data are early and limited; some warn it’s too soon to extrapolate material commercial potential, which could lead to profit‑taking or volatility. Sarepta Therapeutics: It’s Too Early To Get Excited About siRNA Data

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.